The GLP-1 analogue exenatide improves hepatic and muscle insulin sensitivity in diabetic rats: Tracer studies in the basal state and during hyperinsulinemic-euglycemic clamp

Journal of Diabetes Research

Volumn 2014, Issue , 2014, Pages

  Wu, Hui ^a   Sui, Chunhua ^a   Xu, Hui ^a   Xia, Fangzhen ^a   Zhai, Hualing ^a   Zhang, Huixin ^a   Weng, Pan ^a   Han, Bing ^a   Du, Sichun ^a   Lu, Yingli ^a  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLUCOSE; GLYCEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; GLP1R PROTEIN, RAT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON RECEPTOR; GLUCOSE BLOOD LEVEL; LIPID; PEPTIDE; STREPTOZOCIN; VENOM;

ANIMAL EXPERIMENT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; GASTROCNEMIUS MUSCLE; GLUCONEOGENESIS; GLUCOSE ABSORPTION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TRANSPORT; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN SENSITIVITY; LIVER; MALE; MUSCLE; NONHUMAN; RAT; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TRIACYLGLYCEROL BLOOD LEVEL; AGONISTS; ANIMAL; BLOOD; CHEMICALLY INDUCED; COMPARATIVE STUDY; DIABETES MELLITUS, EXPERIMENTAL; DIET RESTRICTION; DRUG EFFECTS; GLUCOSE CLAMP TECHNIQUE; INSULIN RESISTANCE; LIPID DIET; METABOLISM; SKELETAL MUSCLE; SPRAGUE DAWLEY RAT;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIET, HIGH-FAT; FASTING; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLUCONEOGENESIS; GLUCOSE CLAMP TECHNIQUE; GLYCEROL; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; LIPIDS; LIVER; MALE; MUSCLE, SKELETAL; PEPTIDES; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLUCAGON; STREPTOZOCIN; VENOMS;

EID: 84919343759     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2014/524517     Document Type: Article

References (29)

1. Schirra J., Sturm K., Leicht P., Arnold R., Goke B., Katschinski M., Exendin (9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans. The Journal of Clinical Investigation 1998 101 7 1421 1430
2. Schirra J., Nicolaus M., Roggel R., Katschinski M., Storr M., Woerle H. J., Göke B., Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans. Gut 2006 55 2 243 251 2-s2.0-30944467225 10.1136/gut.2004.059741
3. Deane A. M., Nguyen N. Q., Stevens J. E., Fraser R. J. L., Holloway R. H., Besanko L. K., Burgstad C., Jones K. L., Chapman M. J., Rayner C. K., Horowitz M., Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia. Journal of Clinical Endocrinology and Metabolism 2010 95 1 215 221 10.1210/jc.2009-1503 2-s2.0-75149127635
4. Wajcberg E., Tavaria A., Exenatide: clinical aspects of the first incretin-mimetic for the treatment of type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy 2009 10 1 135 142 10.1517/14656560802611832 2-s2.0-65549124145
5. Mafong D. D., Henry R. R., Exenatide as a treatment for diabetes and obesity: implications for cardiovascular risk reduction. Current Atherosclerosis Reports 2008 10 1 55 60 10.1007/s11883-008-0009-z 2-s2.0-40749161446
6. Edwards C. M., Stanley S. A., Davis R., Brynes A. E., Frost G. S., Seal L. J., Ghatei M. A., Bloom S. R., Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. The American Journal of Physiology-Endocrinology and Metabolism 2001 281 1 E155 E161 2-s2.0-0034814047
7. Arnés L., González N., Tornero-Esteban P., Sancho V., Acitores A., Valverde I., Delgado E., Villanueva-Peñacarrillo M. L., Characteristics of GLP-1 and exendins action upon glucose transport and metabolism in type 2 diabetic rat skeletal muscle. International Journal of Molecular Medicine 2008 22 1 127 132 2-s2.0-52049122152
8. Bi Y., Cai M., Liang H., Sun W., Li X., Wang C., Zhu Y., Chen X., Li M., Weng J., Increased carnitine palmitoyl transferase 1 expression and decreased sterol regulatory element-binding protein 1c expression are associated with reduced intramuscular triglyceride accumulation after insulin therapy in high-fat-diet and streptozotocin-induced diabetic rats. Metabolism: Clinical and Experimental 2009 58 6 779 786 10.1016/j.metabol.2009.01.011 2-s2.0-65549167291
9. Guo Z., Zhou L., Dual tail catheters for infusion and sampling in rats as an efficient platform for metabolic experiments. Lab Animal 2003 32 2 45 48 10.1038/laban0203-45 2-s2.0-0037315874
10. Mahin D. T., Lofberg R. T., A simplified method of sample preparation for determination of tritium, carbon-14, or sulfur-35 in blood or tissue by liquid scintillation counting. Analytical Biochemistry 1966 16 3 500 509 2-s2.0-0001663296 10.1016/0003-2697(66)90233-8
11. Vella A., Rizza R. A., Application of isotopic techniques using constant specific activity or enrichment to the study of carbohydrate metabolism. Diabetes 2009 58 10 2168 2174 10.2337/db09-0318 2-s2.0-70349642926
12. Peroni O., Large V., Beylot M., Measuring gluconeogenesis with [2-13C]glycerol and mass isotopomer distribution analysis of glucose. The American Journal of Physiology-Endocrinology and Metabolism 1995 269 3 E516 E523 2-s2.0-0029360338
13. Guo Z., Zhou L., Muscle type-dependent responses to insulin in intramyocellular triglyceride turnover in obese rats. Obesity Research 2005 13 12 2081 2087 10.1038/oby.2005.258 2-s2.0-33645047450
14. Kraegen E. W., James D. E., Bennett S. P., Chisholm D. J., In vivo insulin sensitivity in the rat determined by euglycemic clamp. The American Journal of Physiology 1983 245 1 E1 E7 2-s2.0-0020791161
15. Guo Z., Jensen M. D., Blood glycerol is an important precursor for intramuscular triacylglycerol synthesis. Journal of Biological Chemistry 1999 274 34 23702 23706 10.1074/jbc.274.34.23702 2-s2.0-0033588373
16. Wu H., Xia F.-Z., Xu H., Zhai H.-L., Zhang M.-F., Zhang H.-X., Li Y.-X., Li Y., Gu T., Ma L.-M., Lu Y.-L., Acute effects of different glycemic index diets on serum motilin, orexin and neuropeptide Y concentrations in healthy individuals. Neuropeptides 2012 46 3 113 118 10.1016/j.npep.2012.02.001 2-s2.0-84862787415
17. Bradley D. P., Kulstad R., Schoeller D. A., Exenatide and weight loss. Nutrition 2010 26 3 243 249 10.1016/j.nut.2009.07.008 2-s2.0-75749139750
18. Vaughan M., The production and release of glycerol by adipose tissue incubated in vitro. The Journal of Biological Chemistry 1962 237 3354 3358 2-s2.0-0001072302
19. Boden G., Obesity, insulin resistance and free fatty acids. Current Opinion in Endocrinology, Diabetes and Obesity 2011 18 2 139 143 10.1097/MED.0b013e3283444b09 2-s2.0-79952451443
20. Klonoff D. C., Buse J. B., Nielsen L. L., Guan X., Bowlus C. L., Holcombe J. H., Wintle M. E., Maggs D. G., Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Current Medical Research and Opinion 2008 24 1 275 286 10.1185/030079907X253870 2-s2.0-38549162147
21. Zheng D., Ionut V., Mooradian V., Stefanovski D., Bergman R. N., Exenatide sensitizes insulin-mediated whole-body glucose disposal and promotes uptake of exogenous glucose by the liver. Diabetes 2009 58 2 352 359 10.2337/db08-0875 2-s2.0-63249084223
22. Basu R., Schwenk W. F., Rizza R. A., Both fasting glucose production and disappearance are abnormal in people with "mild" and "severe" type 2 diabetes. American Journal of Physiology: Endocrinology and Metabolism 2004 287 1 E55 E62 10.1152/ajpendo.00549.2003 2-s2.0-3042701667
23. Landau B. R., Wahren J., Chandramouli V., Schumann W. C., Ekberg K., Kalhan S. C., Contributions of gluconeogenesis to glucose production in the fasted state. The Journal of Clinical Investigation 1996 98 2 378 385 10.1172/JCI118803 2-s2.0-0030017082
24. Rothman D. L., Magnusson I., Katz L. D., Shulman R. G., Shulman G. I., Quantitation of hepatic glycogenolysis and gluconeogenesis in fasting humans with 13C NMR. Science 1991 254 5031 573 576 10.1126/science.1948033 2-s2.0-0026320213
25. DeFronzo R. A., Tripathy D., Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care 2009 32 supplement 2 S157 S163 2-s2.0-75549085755 10.2337/dc09-S302
26. Lillioja S., Mott D. M., Howard B. V., Bennett P. H., Yki-Jarvinen H., Freymond D., Nyomba B. L., Zurlo F., Swinburn B., Bogardus C., Impaired glucose tolerance as a disorder of insulin action. Longitudinal and cross-sectional studies in Pima Indians. The New England Journal of Medicine 1988 318 19 1217 1225 10.1056/NEJM198805123181901 2-s2.0-0023924773
27. Warram J. H., Martin B. C., Krolewski A. S., Soeldner J. S., Kahn C. R., Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Annals of Internal Medicine 1990 113 12 909 915 10.7326/0003-4819-113-12-909 2-s2.0-0025663581
28. Ferrannini E., Simonson D. C., Katz L. D., Reichard G. Jr., Bevilacqua S., Barrett E. J., Olsson M., DeFronzo R. A., The disposal of an oral glucose load in patients with non-insulin-dependent diabetes. Metabolism 1988 37 1 79 85 10.1016/0026-0495(88)90033-9 2-s2.0-0023838435
29. Thiebaud D., Jacot E., DeFronzo R. A., Maeder E., Jequier E., Felber J. P., The effect of graded doses of insulin on total glucose uptake, glucose oxidation, and glucose storage in man. Diabetes 1982 31 11 957 963 2-s2.0-0019935341 10.2337/diacare.31.11.957